Molecular Imaging and Its Role in the Management of Breast Cancer

Kiser, Jackson W.

doi:10.1097/grf.0000000000000186

Cited by 3 publications

(2 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2 Unlike conventional imaging which, in general, detects the anatomic or phenotypic changes that occur as the end result of a biologic process, molecular imaging helps to identify more subtle changes non-invasively, even at cellular or molecular levels, before detectable changes in the phenotype have developed. [3][4][5][6] For early detection of breast cancer, in which repetitive imaging examinations are warranted (eg, dense breast tissue for which mammography has limited accuracy for detecting breast cancer), ultrasound molecular imaging (USMI) is advantageous because it can detect small foci of cancer with high sensitivity and specificity without the use of potentially harmful ionizing radiation. Also, USMI is less expensive compared with other imaging methods.…”

Section: Introductionmentioning

confidence: 99%

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Wan

et al. 2018

IJN

View full text Add to dashboard Cite

BackgroundThe development of nanoscale molecularly targeted ultrasound contrast agents (UCAs) with high affinity and specificity is critical for ultrasound molecular imaging in the early detection of breast cancer.PurposeTo prospectively evaluate ultrasound molecular imaging with dual-targeted gold nanoshelled poly(lactide-co-glycolic acid) nanocapsules carrying vascular endothelial growth factor receptor type 2 (VEGFR2) and p53 antibodies (DNCs) in MCF-7 orthotopic mice model.MethodsDNCs were fabricated with an inner PLGA and outer gold nanoshell spherical structure. Its targeting capabilities were evaluated by confocal laser scanning microscopy (CLSM) and flow cytometry (FCM) in vitro. Contrast-enhanced ultrasound imaging (CEUS) with DNCs was evaluated qualitatively and quantitatively in vitro and in MCF-7 orthotopic mice model by two different systems. The biodistribution of NCs in mice was preliminary investigated. Differences were calculated by using analysis of variance.ResultsDNCs showed a well-defined spherical morphology with an average diameter of 276.90±110.50 nm. In vitro, DNCs exhibited high target specificities (79.01±5.63% vs. 2.11±1.07%, P<0.01; 75.54±6.58% vs. 5.21±3.12%, P<0.01) in VEGFR2- and p53-positive cells compared with control cells. In vivo, CEUS displayed a significantly higher video intensity in two systems using DNCs in comparison with non-targeted PLGA@Au NCs and single-targeted NCs. Biodistribution studies revealed that more DNCs in breast cancer tissue could be detected in mice than in other NCs (P<0.05).ConclusionDNCs were demonstrated to be novel dual-targeted UCAs and may have potential applications in early non-invasive visualization of breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Wan

et al. 2018

IJN

View full text Add to dashboard Cite

show abstract

“…In PET/CT, the CT component is used for attenuation correction and for anatomic correlation and characterization of neoplastic lesions, whereas the PET component is used to identify lesions with increased radiotracer uptake (3,4). In breast cancer, clinical PET/CT has been used mainly as a whole-body examination for disease detection, therapy follow-up, and response assessment, as well as for prognostic stratification (5). Despite promising results with PET mammography (PEM), the predominant diagnostic imaging tools for local staging are conventional mammography, ultrasound, and MRI (6)(7)(8).…”

mentioning

confidence: 99%

Feasibility of ¹⁸F-FDG Dose Reductions in Breast Cancer PET/MRI

et al. 2018

View full text Add to dashboard Cite

The goal of this study was to determine the level of clinically acceptable F-FDG dose reduction in time-of-flight PET/MRI in patients with breast cancer. Twenty-six consecutive women with histologically proven breast cancer were analyzed (median age, 51 y; range, 34-83 y). Simulated dose-reduced PET images were generated by unlisting the list-mode data on PET/MRI. The acquired 20-min PET frame was reconstructed in 5 ways: a reconstruction of the first 2 min with 3 iterations and 28 subsets for reference, and reconstructions simulating 100%, 20%, 10%, and 5% of the original dose. General image quality and artifacts, image sharpness, image noise, and lesion detectability were analyzed using a 4-point scale. Qualitative parameters were compared using the nonparametric Friedman test for multiple samples and the Wilcoxon signed-rank test for paired samples. Different groups of independent samples were compared using the Mann-Whitney test. Overall, 355 lesions (71 lesions with 5 different reconstructions each) were evaluated. The 20-min reconstruction with 100% injected dose showed the best results in all categories. For general image quality and artifacts, image sharpness, and noise, the reconstructions with a simulated dose of 20% and 10% were significantly better than the 2-min reconstructions ( ≤ 0.001). Furthermore, 20%, 10%, and 5% reconstructions did not yield results different from those of the 2-min reconstruction for detectability of the primary lesion. For 10% of the injected dose, a calculated mean dose of 22.6 ± 5.5 MBq (range, 17.9-36.9 MBq) would have been applied, resulting in an estimated whole-body radiation burden of 0.5 ± 0.1 mSv (range, 0.4-0.7 mSv). Ten percent of the standard dose ofF-FDG (reduction of ≤90%) results in clinically acceptable PET image quality in time-of-flight PET/MRI. The calculated radiation exposure would be comparable to the effective dose of a single digital mammogram. A reduction of radiation burden to this level might justify partial-body examinations with PET/MRI for dedicated indications.

show abstract

How to survive and thrive as a new breast imager: what they don't teach in fellowship

Omofoye

Parikh

2019

Clinical Imaging

View full text Add to dashboard Cite

Molecular Imaging and Its Role in the Management of Breast Cancer

Cited by 3 publications

References 23 publications

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Feasibility of ¹⁸F-FDG Dose Reductions in Breast Cancer PET/MRI

How to survive and thrive as a new breast imager: what they don't teach in fellowship

Contact Info

Product

Resources

About

Molecular Imaging and Its Role in the Management of Breast Cancer

Cited by 3 publications

References 23 publications

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Ultrasound molecular imaging of breast cancer in MCF-7 orthotopic mice using gold nanoshelled poly(lactic-co-glycolic acid) nanocapsules: a novel dual-targeted ultrasound contrast agent

Feasibility of 18F-FDG Dose Reductions in Breast Cancer PET/MRI

How to survive and thrive as a new breast imager: what they don't teach in fellowship

Contact Info

Product

Resources

About

Feasibility of ¹⁸F-FDG Dose Reductions in Breast Cancer PET/MRI